| section Home
Production, Amateur Radio amateur Model aircraft, rocket- Useful, entertaining |
Stealth master
Electronics Physics Technologies invention |
space Mystery
Earth Mysteries Secrets of the Ocean Stealth section Map |
  |
| Use of material is permitted for reference (for websites - hyperlinks) | |||
Navigation: => |
Home / Products Patents / In the section of the catalog / back / |
|
INVENTION
Russian Federation Patent RU2286162
METHOD OF TREATMENT cutaneous manifestations SCLERODERMA
Name of the inventor: Kozlovsky Emma P. (RU); Artyukov Alexander A. (RU); Alex Kozlowski Stefanovic (RU); Male Aleksey Viktorovich (RU); Vyacheslav V. Barbin (RU); Ozerskaya Olga (RU); Atamanchuk Anna A. (RU)
The name of the patentee: Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Sciences
Address for correspondence: 690022, Vladivostok, Prospect 100 years of Vladivostok, 159, Pacific Institute of Bioorganic Chemistry, Patent Department, NI Stadnichenko
Starting date of the patent: 2005.04.19
The invention relates to medicine, namely to dermatology, and can be used for the treatment of focal scleroderma. In this preparation "Collagenase QC" intradermally injected directly into the center of pathology in multiple injections of a therapeutic dose to a depth of 2-3 mm at a distance of approximately 1 cm from each other, wherein the treatment is 10-20 sessions sessions performed 1 time 7- 10 days. The method enhances the efficiency of treatment by penetration of the drug in the pathology of the hearth at a depth of 2-3 mm, and a simplification of treatment.
DESCRIPTION OF THE INVENTION
The invention relates to medicine, in particular to the field of dermatology, and can be used for the treatment of scleroderma.
Scleroderma - a serious chronic disease that affects the connective tissue. This is manifested, as a rule, in the form of seals. Reasons for scleroderma so far not been fully established. At the heart of the development of scleroderma, a key role is played by functional disorders of fibroblasts and other cells kollagenoobrazuyuschih. Of particular importance are the autoimmune response to collagen. It is believed that multiple endocrine, metabolic, neurological, genetic, pathological influences, combined with the damaging influence of external factors that contribute to the formation of pathological changes in the connective tissue system, not only the skin and blood vessels, and internal organs.
For the treatment of dermatoses invited to a lot of different methods, including the use of antifibrotic, vasoactive, trophic, anti-inflammatory, immuno-, corticosteroids, detoxification drugs, preformed physical factors (ultrasound, laser, etc.), External agents.
A method of treating localized scleroderma, consists in the fact that lesions smeared 2-3 times daily 50-70% ethyl pepsidilovm rastovorom Dimexidum [RU 2018307 C1, 30.08.1994].
A method of treating systemic scleroderma xymedon by electrophoresis, 2-3 year course of 20 treatments and inside of 0.5 g 3 times a day for 5 weeks with a break for 2-3 months [RU 2002116907 A, 20.01.2004].
Describes treatment of cutaneous manifestations of scleroderma drug comprising hyaluronidase enzyme produced by the strain Streptomyces actinocidus, and mannitol. The drug is recommended for use externally in the form of bandages or by electrophoresis. The bandage is applied daily for 16-18 hours for 15-60 days or 15-20 sessions of electrophoresis. Use of the drug is combined with other treatments - physiotherapy, anti-inflammatory, analgesic, etc. [RU 2005488 C1, 01.15.1994]..
Common shortcomings of known methods for the treatment of scleroderma are their long, complex, mnogokursovoy character. Often the treatment is ineffective. Application of large amounts of various drugs results in substantial drug load to the patient's body, the danger of side reactions.
In the available patent and other scientific and technical literature is not detected by the methods of treating scleroderma interdermalnogo administration of the drug directly to the fire.
Object of the invention - to develop a new, more efficient and more simple way to treat scleroderma.
The task solved by a method of treatment of scleroderma, wherein the inventive drug pathogenetically sound "Collagenase KK" intradermally injected directly into the hearth pathologies in a therapeutic dose rate 1 every 7-10 days 10-15 sessions.
Injections produce a depth of 2-3 mm for prick prick at a distance of approximately 1 cm from each other with special needles.
The concentration of the enzyme preparation "Collagenase KK" U 250 in 2 ml of saline.
The recommended number of courses - 1-3 at intervals of 1 month. The number of sessions increases in proportion to the density and the existence of pockets of limitation. The sooner treatment is started, the faster the more pronounced clinical effect.
In the present method of treatment of scleroderma using the drug "Collagenase QC", designed and manufactured by the Pacific Institute of Bioorganic Chemistry, FEB RAS (Vladivostok) [RU 2093166 C1, 20.10.1997; Pharmacopeial article 42-0170049200 enterprise approved 01.11.2000].
Collagenase QC selectively acts on collagen in scleroderma foci, causing its destruction. enzyme does not act on other skin structures. QC Collagenase activity is highly specific, rare frequency of allergic reactions in patients.
The technical result - increasing the effectiveness of the treatment due to the introduction of the 100% of the drug directly to the pathology focus, to facilitate the completion of treatment, no iatrogenic effect.
The technical result is ensured by the fact that 100% of the specific enzyme preparation "Collagenase QC" pathogenetic effect on problem areas, ie penetrating into the thickness of the scar to a depth of 2-3 mm, the drug acts directly on the morphological substrate disease outbreak (in collagen, which is necessary to destroy).
As a result, the effectiveness of treatment of scleroderma enzyme preparation increases, achieved good clinical and cosmetic effect. There is a significant reduction in the centers of sight, or their disappearance. It improves the quality of skin in the outbreak, achieved clinical remission in relation to the progression of the outbreak; stored mobility skin and soft tissue, joint function is preserved.
Intradermal administration of the drug "Collagenase QC" through the modern technique of mesotherapy gives a positive result due to the specific effect of the drug (pharmacological effect) and by reflexogenic and humoral effects on distant organs and systems.
The inventive method is characterized by the absence of iatrogenic effects associated with taking medication, occurring in the known methods of treating scleroderma.
The proposed method does not require the use of other drugs, in addition to the drug, "Collagenase QC", it is more simple in execution (can be used in any maloosnaschennom fizioapparaturoy medical office, including any rural hospital).
The method comprises the following procedures:
1. Statement of Allergic tests for the drug and monitor the response of the body within a week.
2. Field Processing various antiseptics.
3. Preparation of injection solution: 250 dilution of the drug U "Collagenase KK" 2 ml of physiological solution or novocaine solution, if necessary anesthesia in patients with decreased pain threshold.
4. The introduction of the drug in the lesion multiple injections at a distance of about 1 cm.
5. Drying of the wound with sterile napkins and surface treatment or Kuriozin chitosan gel.
Patients treated by the proposed method was carried out at the department of skin and venereal diseases of the Military Medical Academy (St. Petersburg).
Example 1. Podgaisky Mikhail, 23 years old. Treatment Date: December 1, 2003. Complaints about unsightly view, the emergence of new growth and progression of scleroderma lesions.
The diagnosis: localized scleroderma trunk and extremities.
History of the disease: sick about 6 years old, on the stomach, back, upper limbs, there are 8 homes, presented a variety of sizes, round seal with pockets of lightly pigmented, not rising above the level of the skin. Outbreaks are located on the background of the skin intact. Complaints about the state of health does not show. Allergic history - an allergic reaction to penicillin and procaine.
Status Localis: For the treatment was taken center located on the back surface of the right forearm, size 4,5 × 5 cm, round shape, sharp edges, existing for about a year.
intradermal test tolerance collagenase QC was performed before treatment. The sample is negative. Treatment was conducted by introducing CC collagenase in the hearth 1 time per week. In the course of treatment carried out 15 sessions. Patient treatment is well tolerated.
As a result, a 3.5-month rate was the focus of the color closer to the color of the surrounding tissue, become softer at 50%, 40% decreased in size, the edges become blurred. The patient is satisfied with the treatment.
Example 2: Nicholas G. Taranov, 52 years old. Treatment Date: May 5, 2004 Complaints about the itch in the field of focus on the back, a burning sensation, a cosmetic defect. Diagnosis: Superficial localized scleroderma the back.
History of the disease: ill for about a year. The hearth 1, is located on the background of the skin intact. Complaints about the state of health did not show, allergic history calm.
Status localis: center located at the back, size 10 × 5 cm, rises above the level of the skin, hyperpigmented, crisp edges, sealed.
intradermal test tolerance collagenase QC was performed before treatment. The sample is negative. Treatment was conducted by introducing CC collagenase in the hearth 1 time per week. In the course of treatment carried out 10 sessions. Patient treatment is well tolerated.
As a result of the treatment center has become almost visible in the background of healthy skin, less dense, the edges are blurred. Gone are itching and burning sensation. The patient is satisfied with the treatment.
CLAIM
A method of treating cutaneous manifestations of scleroderma, wherein the drug "Collagenase QC" intradermally injected directly into the center of pathology in multiple injections of therapeutic dose to a depth of 2-3 mm at a distance of approximately 1 cm from each other, with a course of treatment sessions 10-20 , sessions conducted 1 time in 7-10 days.
print version
Publication date 06.01.2007gg
Comments
Commenting, keep in mind that the content and the tone of your messages can hurt the feelings of real people, show respect and tolerance to his interlocutors, even if you do not share their opinion, your behavior in terms of freedom of speech and anonymity offered by the Internet, is changing not only virtual, but real world. All comments are hidden from the index, spam control.